XLO   $0.818  2.25% Market Closed

Xilio Therapeutics, Inc.
Total Cash 74.95M
totalCashPerShare 1.705
EBITDA -64.91M
Total Debt 8.69M
quickRatio 1.94
currentRatio 2.019
Total Revenue 2.36M
debtToEquity 26.003
Revenue/Share 0.054
ROA -0.45755002
ROE -1.30031
grossProfits
freeCashflow -3.61M
operatingCashflow -17.34M
earningsGrowth
revenueGrowth
grossMargins 1.0
ebitdaMargins 0.0
operatingMargins -6.22571
profitMargins 0.0
enterpriseValue -9.56M
forwardPE -2.224138
floatShares 22.62M
sharesOutstanding 43.95M
sharesShort 104.75K
sharesShortPriorMonth 14.75K
dateShortInterest
sharesPercentSharesOut 0.00%
heldPercentInsiders 0.41%
heldPercentInstitutions 0.30%
Short Ratio help_outline 0.76%
shortPercentOfFloat 0.00%
impliedSharesOutstanding
bookValue 0.76
Price To Book help_outline 1.70
earningsQuarterlyGrowth
netIncomeToCommon -65.53M
trailingEps -1.95%
forwardEps -0.58%
enterpriseToEbitda 0.15
lastDividendValue
lastDividendDate
currentQuarterEstimate -0.25 3Q 2024
institutionsCount 35
lastUpdated Nov. 7, 2024, 6:57 a.m.